You may be eligible if you:
Are aged 18 or over
Have been diagnosed with both PSC and inflammatory bowel disease (IBD)
Are able to give your own consent to take part
If you take part, you will be in the study for 5 years. You'll be randomly allocated to receive either low-dose aspirin (75mg daily) or a placebo — you have a 2 in 3 chance of receiving the active aspirin. Neither you nor the study team will know which you have been allocated.
You'll attend your usual hospital for visits approximately every 6 months — 12 visits in total over the 5 years. At each visit you'll have a brief health review, blood tests, and complete questionnaires. You'll continue to receive your normal PSC monitoring throughout, including annual colonoscopies and liver scans.
Over 900 volunteers across 60 NHS hospitals are being recruited for this study. Your participation could help find the first effective treatment to reduce cancer risk in people with PSC and IBD.
If you're interested in taking part, click below to get started.
This study has been reviewed and approved by a Research Ethics Committee (IRAS no.: 1007320, REC Number 23/WA/0282). Sponsored by Imperial College London and funded by Cancer Research UK. For more information, visit www.pscsupport.org.uk/asp
